Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer

Inclusion Criteria: * Patients must have persistent, metastatic, or recurrent platinum resistant or refractory ovarian or primary peritoneal cancer. * No restriction on previous treatment regimens, but patients must be at least 2 weeks out from last chemotherapy or investigational agent. * Patients must be \>= 18. * Patients must have a life expectancy of at least 6 months. * Patients must have KPS \>= 60. * Patients must have acceptable organ and marrow function as defined below (within 2 weeks prior to radiotherapy): * leukocytes \>=3,000/uL * absolute neutrophil count \>=1,500uL * platelets \>=100,000/uL * total bilirubin within 1.5X normal institutional limits * AST(SGOT)/ALT(SGPT) \<2.5 X institutional upper limit of normal * creatinine within normal institutional limits OR * creatinine clearance \>=60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal * Patients must be willing to undergo a pre- and post-treatment FDG-PET/CT. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Patients should not have received radiation overlapping with the proposed treatment field. * Patients cannot be receiving chemotherapy or other investigation agents from two weeks prior to radiation through undergoing their post-therapy FDG-PET/CT * Patients cannot be pregnant or nursing. * Patients cannot have disease \>= 8cm or greater than 3 regions of disease. * Patients cannot have concurrent malignancy other than non-melanoma skin cancer, non-invasive bladder cancer, or carcinoma in situ of the cervix.